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Katharine B. Simmons, MD, MPH; Lisa B. Haddad, MD, MS, MPH; Kavita Nanda, MD, MHS;
Kathryn M. Curtis, PhDOBJECTIVE: The purpose of this study was to determine whether interactions between
non-rifamycin antibiotics and hormonal contraceptives result in decreased effectiveness
or increased toxicity of either therapy.
STUDY DESIGN: We searched MEDLINE, Embase, clinicaltrials.gov, and Cochrane li-
braries from database inception through June 2016. We included trials, cohort, case-
control, and pharmacokinetic studies in any language that addressed pregnancy
rates, pharmacodynamics, or pharmacokinetic outcomes when any hormonal contra-
ceptive and non-rifamycin antibiotic were administered together vs apart. Of 7291
original records that were identified, 29 met criteria for inclusion.
STUDY APPRAISAL AND SYNTHESIS METHODS: Two authors independently assessed
study quality and risk of bias using the United States Preventive Services Task Force
evidence grading system. Findings were tabulated by drug class.
RESULTS: Study quality ranged from good to poor and addressed only oral contraceptive
pills, emergency contraception pills, and the combined vaginal ring. Two studies
demonstrated no difference in pregnancy rates in women who used oral contraceptives
with and without non-rifamycin antibiotics. No differences in ovulation suppression or
breakthrough bleeding were observed in any study that combined hormonal contra-
ceptives with any antibiotic. No significant decreases in any progestin pharmacokinetic
parameter occurred during co-administration with any antibiotic. Ethinyl estradiol area
under the curve decreased when administered with dirithromycin, but no other drug.
CONCLUSION: Evidence from clinical and pharmacokinetic outcomes studies does not
support the existence of drug interactions between hormonal contraception and non-
rifamycin antibiotics. Data are limited by low quantity and quality for some drug clas-
ses. Most women can expect no reduction in hormonal contraceptive effect with the
concurrent use of non-rifamycin antibiotics.
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JANUARY 2018interactions betweenHC and antibiotics,
such as induction or inhibition of he-
patic enzymes by either drug, theoreti-
cally could compromise contraceptive or
antibiotic effect.2 However, clinical con-
cerns of drug interactions between anti-
biotics and HC are based primarily on
case reports of unintended pregnancies
in HC users and patient and provider
surveys that are limited severely by recall
bias.2 Likewise, although rifamycin an-
tibiotics (rifampin, rifabutin) induce
hepatic enzymes that are required forHC
metabolism, other antibiotics do not;
assumption of similar behavior of all
antibiotic drugs may be inappropriate.3
Misconceptions regarding HC and
drug interactions are common among
women, providers, and pharmacists; a
majority of pharmacists recommend
backup contraception for women who
use antibiotics with HC.4 Such warnings
could result in interruption of a woman’s
HC or poor compliance with antibiotic
regimens, which could increase her risk
for treatment failure with either drug. If
no true drug interaction is present, these
risks are assumed unnecessarily.
Objectives
The purpose of this systematic review
was to evaluate published literature on
the interaction of non-rifamycin antibi-
otics and HC. Specifically, we addressed
the following research question: Among
women taking HC or non-rifamycin
antibiotics, do users who take these
drugs together experience decreased
contraceptive or antibiotic effectiveness
or increased hormonal or antibiotic
toxicity compared with users who take
each drug alone?
Methods
This systematic review was conducted
according to an a priori protocol with
similar methods to previous World
TABLE 1
Summary of evidence from observational studies
Study Study design Data source Exposures Size Outcomes Interaction Quality
Helms et al11 Retrospective
cohort
3 Dermatology
practices
Any OC  any
concurrent
antibiotic use
356 Exposed; 425
unexposed
Pregnancy rates
in antibiotic
exposed vs
unexposed OC
users
4 II-2, Fair
Jick et al12 Nested case
control
United Kingdom
database of
general
practitioners
Any OC or patch
 any antibiotic
use within 16
weeks of
conception
1129 Cases; 4374
controls
Odds of
unintended
pregnancy while
on OCs in
antibiotic users vs
nonusers
4 II-2, Poor
Koopmans et al14 Case cross-over Pharmacy
dispensing
database in the
Netherlands
Any OC use; any
antibiotic script
within 15 days of
conception
397 Cases; self-
matched controls
Odds of antibiotic
exposure during
conception vs
control time
periods in OC
failure
pregnancies
4 II-2, Poor
Toh et al13 Case cross-over Sloane
Epidemiology
Center Birth
Defects Study and
National Birth
Defects
Prevention Study
Any OC use during
month of
conception; any
antibiotic use in 4
weeks before
conception
1330 Cases; self-
matched controls
Odds of antibiotic
exposure during
conception vs
control time
periods in OC
failure
pregnancies
4 II-2, Fair
4, no difference in the outcome between cases and controls; OC, oral contraceptive pill.
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ajog.org Systematic ReviewsHealth Organization and Centers for
Disease Control systematic reviews for
contraceptive guidance5,6 (protocol
available on request). We report this
systematic review according to Preferred
Reporting Items for Systematic Reviews
and Meta-Analyses guidelines.7
Eligibility criteria, information
sources, and search strategy
Types of studies.We included randomized
and nonrandomized controlled trials,
cohort studies, and case-control studies.
Abstracts, case reports and series, cross-
sectional studies, editorials, letters, and
nonpublished results were excluded. All
included studies were required to have a
comparison group; therefore, we also
excluded prospective observational
studies without control groups. For
studies with HC-related outcomes, the
comparison groupwaswomen takingHC
without concurrent antibiotics. For
studies of antibiotic-related outcomes,
the comparison group was women taking
the antibiotic without HC.Participants and interventions.We
included studies of women taking any
method of HC (combined pills, patch,
ring or injectables; progestin-only pills;
ring, injectables, implants or
intrauterine-devices, or emergency con-
traceptive pills) in combination with any
oral, intravenous, or intramuscular non-
rifamycin antibiotic. We excluded
studies of steroid hormones in non-
contraceptive formulations, such as
intravenous estrogen.
Types of outcomes and data items.We
included studies that had at least 1 clin-
ical or pharmacokinetic outcome of
interest. Clinical outcomes of interest
included (1) pregnancy rates, (2) evi-
dence of ovulation by luteal phase serum
progesterone alone or in combination
with a dominant follicle on ultrasound
imaging, (3) antibiotic effectiveness
(treatment response or failure),
and (4) adverse health effects (break-
through bleeding, drug side-effects,
or complications). PharmacokineticJANUARY 2018 Aoutcomes of interest included area
under the curve (AUC), maximum
serum concentration (Cmax), and
steady-state levels of the contraceptive
steroid hormone or the antibiotic. We
excluded studies that reported only uri-
nary excretion of hormones because
these were not considered interpretable
pharmacokinetic findings.
Search strategy.We searched MEDLINE,
Embase, Clinicaltrials.gov, and
Cochrane libraries from inception to
June 2016 for articles in any language
using search terms that were developed
with a reference librarian (Appendix A).
We scanned reference lists of relevant
review articles to identify additional
studies that were not captured by our
search.
Study selection
One author (K.B.S.) performed the
database search in consultation with
a reference librarian and screened all
titles and abstracts. Two authorsmerican Journal of Obstetrics& Gynecology 89
Systematic Reviews ajog.orgreviewed the full text of all possible
articles to determine which articles met
inclusion criteria. Non-English articles
were translated as needed. Any
disagreement between authors on in-
clusion status was resolved with a third
author.
Data extraction
One author independently extracted
relevant information from each study to
complete prespecified evidence tables.
Tables were reviewed for accuracy by a
second author before study grading
(Appendices BeG). We included only
published findings and did not contact
authors to obtain additional
information.
Assessment of risk of bias
We assigned a quality rating for each
study that was based on the overall
evidence it provided for its primary
outcome, according to the United States
Preventative Services Task Force
grading scale (good, fair, poor).8 A
“good” study has no important limita-
tions, and results are considered inter-
nally valid; a “fair” study has clear
limitations but no fatal flaws, and a
“poor” study has 1 fatal flaws that
may invalidate results. In determining
the study quality rating, we assessed
risk of bias using prespecified grading
criteria. For case-control, cohort studies
and nonrandomized trials with only
clinical outcomes, grading criteria for
risk of bias included selection bias,
appropriateness and generalizability of
participants, sample size and power,
exposure assessment, timing of anti-
microbial use, validation of outcomes,
loss to follow up, and confounding.
For trials with pharmacokinetic out-
comes, we used a previously reported
quality rating system to assess study
design, sample size, drug exposure and
adherence, appropriateness of phar-
macokinetic parameters, timing of
blood draws, intersubject variability,
steady state of perpetrator drug, and
validation of assays.9 The quality of
each study was assigned independently
by 2 authors. Any differences were
resolved through discussion with a
third author.90 American Journal of Obstetrics& GynecologyData synthesis
We synthesized findings descriptively.
Observational studies of pregnancy rates
with general antibiotic use were
described first, followed by a summary of
findings for each class of antibiotic.
Metaanalysis could not be conducted
because of heterogeneity of exposures
(different antibiotic drugs, doses, and
progestins) and outcomes (differences in
pharmacokinetic parameters and
timing) and limited studies in most drug
classes.
Results
We identified 7291 articles and 70 studies
on clinicaltrials.gov in our initial search
after removal of duplicates (Figure). Af-
ter review of titles and abstracts, 220 full-
text articles were reviewed. Twenty-nine
articles met inclusion criteria, including
1 article in German.10 No studies on
clinicaltrials.gov met inclusion criteria
that were not already captured by other
databases. We first report observational
studies of pregnancy rates or HC failure
with any antibiotic use (n¼4) and then
report trials of individual antibiotics
with clinical or pharmacokinetic out-
comes (n¼25).
Pregnancy rates and antibiotic use
(Table 1; Appendix B)
Two studies compared pregnancy rates
in women who used HC alone or with
an antibiotic.11,12 In a retrospective
cohort study of 3 dermatology prac-
tices, Helms et al11 surveyed by mail
578 women with a history of concur-
rent exposure to oral contraceptive pills
(OCs) and antibiotics over 5 years. Of
356 women who completed the survey,
263 women also had unexposed time
periods with OC use alone; in-
vestigators surveyed an additional 162
OC users without a record of concur-
rent antibiotic use to complete the
control group. Five pregnancies
occurred among women who were
exposed to HCs and antibiotics (min-
ocycline, 3; cephalosporin, 2); 12 preg-
nancies occurred in women who were
exposed to OCs alone. There was no
difference in pregnancy rates for
women who used OCs alone and
women who used OCs concurrentlyJANUARY 2018with antibiotics (0.96 and 1.6 per 100
women-years, respectively; P¼.4).
Jick et al12 performed a nested case
control study to examine risk factors for
unintended pregnancy within a database
of general practitioners in the United
Kingdom. Cases were women with un-
intended pregnancy or pregnancy
termination who had a prescription for
HC within 4 months before the index
date (date of diagnosis of unintended
pregnancy; n¼1129). Four women per
case who used HC without a docu-
mented unintended pregnancy served as
control subjects, matched by age, prac-
tice, and year. Antibiotic exposure was
determined by prescription for an anti-
biotic within 16 weeks before the index
date. The odds of unintended pregnancy
were similar, regardless of antibiotic use
(odds ratio [OR], 1.0; 95% confidence
interval [CI], 0.8e1.2).
Two studies examined the odds of
antibiotic use at the time of OC fail-
ure.13,14 Toh et al13 used a national birth
defects database to evaluate antibiotic
use in 1330 OC failure pregnancies in a
case crossover study. Women served as
their own controls, with risk factors for
OC failure compared between the time
frame of 0e4 weeks before conception
(case period) to 4e8 weeks before
conception (control period). The rate of
antibiotic use was 4% during the case
period and 3.8% during the control
period (self-matched OR, 1.08; 95% CI,
0.63e1.84). Odds of antibiotic exposure
were also similar with the use of an
alternate control period (8e12 weeks
before conception) or restricting to only
ampicillin/amoxicillin use.
Finally, Koopmans et al14 performed a
case crossover study using an outpatient
pharmacy dispensing database in The
Netherlands. The population included
women who presumably became preg-
nant while taking OCs (based on picking
up an OC refill within the first 3 months
of a pregnancy; n¼397). The exposure
window for any concurrent antibiotic
prescription was 15 days before and after
probable conception; the control win-
dows were 1-month periods that
occurred 2 months (period 1) or 1 year
(period 2) before the exposure window.
Odds of antibiotic use were no higher in
FIGURE
Preferred reporting items for systematic reviews and meta-analyses
(PRISMA) flow diagram
Number of articles identified in initial database search and excluded at each step of the assessment
process.
HC, hormonal contraception.
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windows (control period 1: OR, 2.0; 95%
CI, 0.89e4.79; control period 2: OR,
1.42; 95% CI, 0.64e3.25).
Penicillins/cephalosporins and OCs
(Table 2; Appendix C)
Surrogate measures of contraceptive effec-
tiveness and adverse health effects. Three
small trials evaluated luteal progesterone
levels in women taking OCs with and
without ampicillin; none of the trials
showed evidence of ovulation in cycles
with concurrent ampicillin, and 1 ovula-
tion occurred in a control cycle.15-17 One
observational study reported that 2 of
20 women with previously normal cycles
on OCs experienced breakthrough
bleeding after the addition of ampicillin
500 mg 4 times daily.10
Pharmacokinetic outcomes. Three small
trials found no difference in HC phar-
macokinetic when administered with
ampicillin.16-18 A single sequence cross-
over study of 6 healthy women examined
ethinyl estradiol (EE) and norethindrone
pharmacokinetic during OC alone and
with ampicillin 500 mg twice daily for
5e7 days later in the same cycle.17 EE and
norethindrone AUC and mean plasma
levels were unchanged after the addition
of ampicillin. Likewise, a mixed parallel
group and single sequence crossover
study enrolled 11 postmenopausal
women and administered 3 days of
ampicillin (500 mg 4 times day) on days
5e8 ofOCs.18 Although no statisticswere
given, EE/norethindrone steady-state
plasma values that were presented in
graphic form did not decrease from
baseline after ampicillin was added and
were similar to controls. Back et al16
conducted 2 small single sequence
crossover studies of EE/levonorgestrel
pharmacokinetic in 13 women taking
OCs alone and with ampicillin (500 mg 3
times daily for 8 days during cycle 1 or 2).
EE and levonorgestrel mean plasma
concentrations were no different during
cycles with and without ampicillin.
Two studies addressed pharmacoki-
netic outcomes for penicillins.19,20 Phi-
lipson19 reported plasma ampicillin
levels and AUC in 10 women after a
single 500-mg dose on day 21 of an OCcycle and again on day 28, after a 7-day
OC washout. Mean ampicillin plasma
levels were lower 1 hour after dosing
when administered with the OC
compared with without (values not
provided; P<.05), but at all other time
points were unchanged; the total AUC
and Cmax were no different. Authors
concluded that the difference in ampi-
cillin levels did not appear to be clinically
important. Finally, a study of 4 women
taking OCs reported cephaloridine levels
over 8 hours after a 500-mg intramus-
cular dose on days 21 (with OC) and 28
(after washout).20 Peak serum levels of
cephaloridine were higher on day 28
than on day 21 (23.5 vs 18.9 mg/mL, no
statistics given). The clinical significance
of this difference was not described.
Tetracyclines and OCs (Table 2;
Appendix D)
Three studies demonstrated no differ-
ence in surrogate contraceptive effec-
tiveness or pharmacokinetic outcomes
with tetracyclines.10,21,22 Murphy et al21
performed a mixed parallel group and
single-sequence crossover study of 11
women to evaluate tetracycline and OC
pharmacokinetic when administeredJANUARY 2018 Aseparately and together. EE AUC and
Cmax were unchanged before and after
tetracycline (500 mg every 4 hours for 10
days); norethindrone AUC24 and Cmax
rose after tetracycline was added (AUC,
33.0e57.9 [units not provided]; Cmax,
4.5e6.3 ng/mL; P<.01 for both). Tetra-
cycline AUC0-4 did not differ with and
without OCs. Similarly, Neely et al22
performed a single sequence crossover
study of 24 women taking OCs for 2
cycles, with doxycycline 100 mg twice
daily on days 14e21 during cycle 2.
Norethindrone and EE steady-state levels
on days 18e20 were unchanged during
the control and doxycycline cycles. Days
18e20 serum progesterone concentra-
tions were unchanged and consistent
with anovulation in both cycles. For
adverse health effects, a third study re-
ported that 15 women with previously
normal cycles on OCs reported no
breakthrough bleeding after taking
oxtetracycline (500 mg 4 times daily).10
Fluoroquinolones and OCs (Table 2;
Appendix E)
Surrogate measures of contraceptive effec-
tiveness and adverse health effects. Two
trials reported no ovulation by lutealmerican Journal of Obstetrics& Gynecology 91
TABLE 2
Summary of evidence from trials with pharmacodynamics or pharmacokinetic outcomes
Study Study design Interventions Size, n Outcomes Interactiona Quality
Penicillins
Adlercreutz et al18 Single sequence
crossover within
parallel groups
NET/EE Ampicillin 11 NET PK
EE PK
NET PK:4
EE PK:4
Poor
Back et al16 Single sequence
crossover
LNG/EE Ampicillin 13 LNG PK
EE PK
Serum P
LNG PK:4
EE PK:4
No rise in P
Poor
Friedman et al15 Single sequence
crossover
Ethynodiol acetate/EE
Ampicillin
11 Serum P No rise in P Poor
Hempel et al10 Single sequence
crossover
NET/EE Ampicillin 20 Bleeding changes 0/20 Control vs 2/20
with BTB
Poor
Joshi et al17 Single sequence
crossover
NET/EE Ampicillin 6 NET PK
EE PK
Serum P
NET PK:4
EE PK:4
No rise in P
Fair
Philipson19 Single sequence
crossover
LNG/EE Ampicillin 10 Ampicillin PK Ampicillin mean level
Yat first hour,
otherwise4
Fair
Wise and Reeves20 Single sequence
crossover
OC Cephaloridine
intramuscular
4 Cephaloridine PK Cephaloridine Y Poor
Tetracyclines
Hempel et al10 Single sequence
crossover
NET/EE
Oxtetracycline
15 Bleeding changes 0/15 Control vs 0/15
with BTB
Poor
Murphy et al21 Single sequence
crossover within
parallel groups
NET/EE Tetracycline 11 NET PK
EE PK
Tetracycline PK
NET: [
EE:4
Tetracycline:4
Poor
Neely et al22 Single sequence
crossover
NET/EE Doxycycline 24 NET PK
EE PK
Serum P
NET PK:4
EE PK:4
No rise in P
Fair
Fluoroquinolones
Amsden et al28 Parallel groups OCs/DMPA
Trovafloxacin
20 Trovafloxacin PK Trovafloxacin Y Poor
Back et al27 Single sequence
crossover
LNG/EE Temafloxacin 12 LNG PK
EE PK
Serum P
LNG PK:4
EE PK:4
No rise in P
Fair
Csemiczky et al26 Randomized
crossover
LNG/EE Ofloxacin 20 Serum P
Ultrasound
No ovulation Good
Droppert et al23 Randomized
crossover
DSG/EE Ciprofloxacin 24 Serum P
Ultrasound
No ovulation Poor
Maggiolo et al25 Randomized
crossover
EE/various progestins
Ciprofloxacin
10 Bleeding changes 0/10 Control vs 0/10
with BTB
Poor
Scholten et al24 Randomized
crossover
DSG/EE Ciprofloxacin 24 EE PK
Serum P
EE PK:4
No rise in P
Good
Shain et al29 Parallel groups OC Moxifloxacin 30 Moxifloxacin PK Moxifloxacin Y Fair
Macrolides
Back et al31 Single sequence
crossover
LNG or DSG/EE
Clarithromycin
10 LNG PK
EE PK
Serum P
LNG PK:4
EE PK:4
No rise in P
Fair
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TABLE 2
Summary of evidence from trials with pharmacodynamics or pharmacokinetic outcomes (continued)
Study Study design Interventions Size, n Outcomes Interactiona Quality
Blode et al33 Single sequence
crossover
E2V/DNG
Erythromycin
12 E2V PK
DNG PK
E2V [
DNG [
Fair
Fischer et al34 Parallel groups OCs Azithromycin 25 Azithromycin PK Azithromycin [ Poor
Meyer et al30 Single sequence
crossover
LNG/EE
Roxithromycin
22 Serum P
Ultrasound
No ovulation Fair
Wermeling et al32 Single sequence
crossover
NET/EE Dirithromycin 15 EE PK
Serum P
EE Y
No rise in P
Good
Others antibiotics
Hempel et al10 Single sequence
crossover
NET/EE
Trimethoprim/
sulfamethoxazole
21 Bleeding changes 0/21 Control vs 2/21
with BTB
Poor
Hempel et al10 Single sequence
crossover
NET/EE
Nitrofurantoin
18 Bleeding changes 0/18 Control vs 0/18
with BTB
Poor
Joshi et al35 Parallel groups NET/EE Dapsone 16 NET PK
EE PK
NET PK:4
EE PK: [
Fair
Joshi et al17 Single sequence
crossover
NET/EE
Metronidazole
25 NET PK
EE PK
Serum P
NET PK:4
EE PK:4
No difference in P
Fair
Mehrota et al36 Parallel groups Mestranol/EE
Isoniazid/
streptomycin
83 TB outcomes No difference in TB
outcomes
Poor
Other contraceptive
formulations
Dogterom et al38 Randomized
crossover
ENG/EE CVR
Amoxicillin
16 ENG PK
EE PK
ENG PK:4
EE PK:4
Good
Dogterom et al38 Randomized
crossover
ENG/EE CVR
Doxycycline
16 ENG
EE PK
ENG PK:4
EE PK:4
Good
Pohl et al37 Single sequence
crossover
UPA Erythromycin 18 UPA PK UPA [ Good
a Interaction reflects the outcome with the combination of HC and antibiotic, compared with the outcome drug alone. Direction of interaction represents summary of PK changes to reflect overall
exposure.Y, statistically significant decrease in drug exposure;4, no change in drug exposure; [, statistically significant increase in drug exposure; BTB, breakthrough bleeding; CVR, con-
traceptive vaginal ring; DMPA, depo-medroxyprogesterone acetate; DNG, dienogest; DSG, desogestrel; E2V, estradiol valerate; EE, ethinyl estradiol; ENG, etonogestrel; LNG, levonorgestrel; NET,
norethindrone; OC, oral contraceptive pill; P, progesterone; PK, pharmacokinetics; TB, tuberculosis; UPA, ulipristal acetate.
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ajog.org Systematic Reviewsprogesterone and no difference in
ovarian activity by ultrasound scanning
in OC cycles with and without cipro-
floxacin.23,24 One trial reported no
breakthrough bleeding in OC cycles with
and without ciprofloxacin.25 Two addi-
tional trials reported no ovulation by
serum progesterone and/or monitoring
of follicles on ultrasound scanning inOC
cycles with and without temafloxacin or
ofloxacin.26,27
Pharmacokinetic outcomes. Two studies
reported no change to HC pharmaco-
kinetic with fluoroquinolones.24,27 In a
single sequence crossover study of 12women using OCs over 2 cycles, with a
7-day course of temafloxacin 600 mg
daily starting in cycle 2, steady-state
plasma levels of EE and levonorgestrel
on days 5e8 were no different in the
temafloxacin cycle than with OCs
alone.27 Likewise, a double-blind, ran-
domized controlled crossover study of
24 women using OCs with ciprofloxa-
cin 500 mg twice daily or placebo for
the first 10 days of 2 cycles found no
difference in EE AUC24 or Cmax geo-
metric mean ratios (GMRs) between
cycles.24
Two studies reported small, but clin-
ically unclear, reductions inJANUARY 2018 Afluoroquinolone pharmacokinetic with
OCs.28,29 One parallel group study re-
ported trovafloxacin pharmacokinetic
after a single 200-mg dose in women
using HC (OCs or depot medrox-
yprogesterone acetate) or non-HC.28
Trovafloxacin Cmax and AUC were
lower in the HC group (Cmax, 2.27 vs
1.92 mg/L; AUC, 26.7 vs 20.8 mg/L), and
clearance was higher (7.62 vs 9.96 L/h; all
comparisons P<.004). A second parallel
group study reported moxifloxacin
pharmacokinetic after a single 400-mg
dose for women using OCs or non-
HC.29 They observed no difference in
Cmax between groups, but AUC0-48 wasmerican Journal of Obstetrics& Gynecology 93
Systematic Reviews ajog.org15% lower (P¼.008), and clearance was
20% higher (P¼.015) in the OC group.
The clinical significance of these changes
was not addressed in either study.
Macrolides and OCs (Table 2;
Appendix F)
Surrogate measures of contraceptive effec-
tiveness and adverse health effects. Three
trials reported no ovulation by ultra-
sound scanning and/or luteal progester-
one during OC cycles with and without
roxithromycin, clarithromycin, or diri-
thromycin.30-32 There was also no dif-
ference in breakthrough bleeding
between cycles with and without roxi-
thromycin or dirithromycin.30,32
Pharmacokinetic outcomes. Three studies
reported mixed HC pharmacokinetic
outcomes with macrolides.31-33 Back
et al31 performed a single-sequence
crossover study of 10 OC users and
measured OC steady-state plasma levels
during cycles with and without clari-
thromycin 250 mg twice daily on days
1e7. Day 5e8 EE and levonorgestrel
plasma steady-state levels were un-
changed between the 2 cycles (P>.1),
and 3-ketodesogestrel (the primary
metabolite of desogestrel) increased
slightly with clarithromycin (3.35 vs 1.43
ng/mL; P<.02). Wermeling et al32 re-
ported day-8 EE pharmacokinetic in a
single sequence crossover study of 15
women using OCs alone and with diri-
thromycin 500 mg daily during days
21e28 of cycle 2 and days 1e8 of cycle 3.
They found a small, but significant,
decrease in mean EE AUC (7.6%; P¼.03)
and an increase in EE clearance (10%;
P¼.03) in the dirithromycin cycle, but no
change in Cmax. Blode et al33 reported
pharmacokinetic of estradiol and
dienogest in a single sequence crossover
study of postmenopausal women taking
estradiol valerate (E2V)/dienogest with
and without erythromycin (500 mg 3
times daily for 5 days; n¼12). Contra-
ceptive exposure increased when E2V/
dienogest was administered with eryth-
romycin; estradiol Cmax and AUC24
GMRs were 151% (95% CI, 136e168%)
and 133% (95% CI, 118e150%),
respectively; dienogest Cmax and AUC24
GMRs were 133% (95% CI, 123e144%)94 American Journal of Obstetrics& Gynecologyand 162% (95% CI, 146e180%),
respectively.
A single paper reported azithromycin
pharmacokinetic in 2 small parallel
group studies of women using OCs
(n¼10) or not (n¼15), taking 500 mg
oral azithromycin followed by 250 mg
daily for 4 days.34 The AUC of azi-
thromycin was higher for OC users than
for nonusers (mean difference, 11.4 mg-
h/L; 95% CI, 5.7-17.2 mg-h//L), and
azithromycin clearance was 38% lower
in OC users. Clinical implications were
not evaluated.
Other antibiotics and OCs (Table 2;
Appendix G)
One single sequence crossover study of
10 women examined metronidazole
(400 mg 3 times daily for cycle days
7e14) in combination with OCs.17
Compared with a cycle with OCs alone,
day 14 EE and norethindrone steady
state, Cmax, and AUC24 were not
significantly different. In a group of 25
women (the original 10 plus an addi-
tional 15 women taking the same drug
combination), luteal progesterone was
consistent with ovulation for 3 of 25
metronidazole cycles and 2 of 25 control
cycles.
Joshi et al35 reported OC pharmaco-
kinetic for OCs administered with
dapsone (100 mg 5 days per week) in 10
womenwith leprosy compared with OCs
alone in 6 control women. Norethin-
drone Cmax and AUC24 were similar in
both groups; EE AUC0-8 was higher in
dapsone patients than control patients
(1041 vs 682 pg/mL/hr; P<.05), and EE
Cmax was not significantly different.
In a single sequence crossover study,
Hempel et al10 reported bleeding pat-
terns before and after the addition of
sulfamethoxazole/trimethoprim (3
times daily) or nitrofurantoin (100 mg 4
times daily) to OCs. Compared with a
history of no disordered bleeding with
OCs alone, 2 of 22 women taking sulfa-
methoxazole/trimethoprim reported
disordered bleeding while on the anti-
biotic, and none of 18 women on
nitrofurantoin reported disordered
bleeding.
Finally, Mehrota et al36 followed
tuberculosis disease outcomes in womenJANUARY 2018using isoniazid-based antibiotic regi-
mens with and without OCs over 1 year.
Sputum cultures were negative for all 33
women who received OCs and for 32 of
34 non-OC patients at the end of the
year.
Other contraceptive formulations
(Table 2; Appendix G)
Pohl et al37 reported ulipristal acetate
(UPA) pharmacokinetic in a single
sequence crossover study of 18 healthy
women with and without erythromycin
(500 mg twice daily for 9 days). UPA
Cmax and AUC24 GMRs increased in the
presence of erythromycin (24% [95%
CI, 1e52%] and 224%, [95% CI, 175-
283%], respectively); the primary UPA
metabolite showed an increase in AUC24
of 62% (43e85%) and a decrease in
Cmax by 48% (95% CI, 38e56%). UPA
was well tolerated with and without
erythromycin, and no serious adverse
events occurred.
Dogterom et al38 performed 2 ran-
domized crossover studies of the EE/
etonogestrel contraceptive vaginal ring
(CVR) with and without amoxicillin
(875mg twice daily days 1e10; n¼16) or
with and without doxycycline (100 mg
daily days 1e10; n¼16) over 2 cycles.
With the use of the data in the GMRs and
90%CIs, therewas no difference in EE or
etonogestrel AUC12 with amoxicillin or
AUC24 with doxycycline compared with
control cycles.
Comment
Main findings
Unintended pregnancy is a great concern
for women taking HC with potentially
interacting drugs. In this systematic re-
view, 2 studies of fair-to poor quality
found no increased risk of pregnancy in
OC users taking antibiotics (any type),
compared with OC users not taking an-
tibiotics.11,12 Two additional fair-to-
poor quality studies found no higher
odds of antibiotic use at the time of
conception in OC-breakthrough preg-
nancies than in control time periods.13,14
Although additional older studies that
were excluded from this review reported
contraceptive failure in OC users taking
antibiotics or reported antibiotic use
among women with pill failures, none of
ajog.org Systematic Reviewsthose studies had comparison groups,
which makes it impossible to draw con-
clusions on the role of the antibiotic in
those pregnancies.2
Surrogate markers of contraceptive
effectiveness in this review also support
no interaction between the use of non-
rifamycin antibiotics and HC. Although
most ovulation outcomes were second-
ary and often underpowered
(Appendices CeG), no differences in
ovulation by serum progesterone or ul-
trasound scanning were observed in any
study that combined OCs with ampi-
cillin,15-17 doxycycline,22 temafloxacin,27
ofloxacin,26 ciprofloxacin,23,24 clari-
thromycin,31 roxithromycin,30 diri-
thromycin,32 or metronidazole.17
Likewise, breakthrough bleeding was
either no different than control or
inconclusive in combination with
ampicillin,10 oxtetracycline,10 ciproflox-
acin,25 dirithromycin,32 roxi-
thromycin,30 nitrofurantoin,10 or
trimethoprim/sulfamethoxazole.10
Finally, pharmacokinetic outcomes
were also reassuring for no interaction
between HC and non-rifampicin anti-
biotics. Importantly, no significant de-
creases in any progestin or EE parameter
occurred during co-administration with
antibiotics that included ampicillin or
amoxicillin (4 good-to-poor quality
studies),16-18,38 tetracycline or doxycy-
cline (3 good-to-poor quality
studies),21,22,38 temafloxacin or cipro-
floxacin (2 good-to-fair quality
studies),24,27 clarithromycin or erythro-
mycin (2 fair-quality studies),31,33 or
dapsone or metronidazole (1 fair-quality
study each; Table 2).17,35 UPA geometric
mean peak levels and AUC increased
during co-administration with erythro-
mycin in 1 good quality study.37
Although there is a wide range in qual-
ity and design of these studies, the con-
sistency of results is reassuring that
progestin levels, which are critical to
contraceptive effect, are not reduced
when co-administered with non-
rifamycin antibiotics.
The only statistically significant
decrease in any EE parameter occurred
during co-administration with diri-
thromycin (a drug no longer available in
the United States). EE AUC decreased7.6%, but Cmax was unchanged in 1
good-quality study.32 Decreases in sys-
temically active EE may result in the
development of a dominant follicle
because of insufficient suppression of
folliculogenesis, but ovulation suppres-
sion should still be maintained by sup-
pression of luteinizing hormone by
the progestin component.39 An increase
in some EE and E2V pharmacokinetic
parameters occurred with co-
administration with dapsone and eryth-
romycin, respectively.33,35 Increases in
estrogen exposure theoretically could
affect thrombosis risk, although this
outcome was not addressed in any study.
Combined HCs can also affect meta-
bolism of co-administered antibiotics,
potentially altering safety or effectiveness
profiles. EE is a known moderate inhib-
itor of several cytochrome P450 (CYP)
enzymes and could increase concentra-
tions of drugs that are metabolized by
these enzymes.3 Two poor-quality
studies of cephaloridine and azi-
thromycin reported statistical increases
in antibiotic pharmacokinetic parame-
ters during co-administration with OCs,
which has uncertain clinical significance
but could pose theoretic drug toxicity
concerns.20,34 Although EE is not a
known inducer of CYP enzymes (which
would reduce levels of co-administered
drugs), 2 fair-to-poor quality studies
reported statistical reductions in some
trovafloxacin and moxifloxacin phar-
macokinetic parameters when taken
with OCs, which could pose theoretic
treatment concerns if reductions were
large enough to affect the therapeutic
range.28,29 No change to ampicillin
and tetracycline pharmacokinetic pa-
rameters was seen in 2 fair-to-poor
quality studies with OCs.19,21 None of
these studies reported toxicity or anti-
biotic treatment failure outcomes in
conjunction with pharmacokinetic out-
comes, limiting their interpretation and
utility.
Strengths and limitations
This systematic review has several
strengths. Primarily, we used strict in-
clusion criteria that required that all
studies include a comparison group.
This is important because combinedJANUARY 2018 AHCs have a typical-use failure rate of
9%,40 so it is inappropriate to assume
that combined HC failures in women
who use antibiotics are due to drug
interaction, as was theorized in older
uncontrolled observational studies, case
series, and guidelines that were based on
case reports.2,41 Likewise, our inclusion
of a range of clinical and pharmacoki-
netic outcomes allows for evaluation of
consistency of findings and better
extrapolation to clinical care.
However, this review is limited by the
quality and quantity of published evi-
dence. The observational studies faced
degrees of misclassification bias of
antibiotic and HC exposures and preg-
nancy outcomes (Appendix B). They are
also limited by grouping antibiotics
(which may dilute smaller effects), an
inability to assess contraceptive adher-
ence, and a lack of adjustment for con-
founders. Studies that addressed
ovulation faced limitations that
included small sample sizes and infre-
quent or poorly timed measurements of
progesterone, which may have led to
missed ovulations in some cases
(Appendices CeG). Few studies used
ultrasound scanning to monitor follic-
ular development and rupture; serum
progesterone is itself a surrogate marker
for ovulation. Pharmacokinetic studies
had various weaknesses that included
not assessing adherence to 1 or both
drugs, small sample sizes, use of non-
standardized pharmacokinetic parame-
ters, the use of statistical comparisons
that do not take into account thera-
peutic bioequivalence, a lack of
randomization, and a lack of attention
to potential confounders (Appendices
CeG). It is also difficult to draw clin-
ical conclusions from pharmacokinetic
studies alone because minimum efficacy
thresholds are not established for EE or
progestins.42 Finally, only 1 study
examined a non-OC formulation
(CVR).38 No data exist on the combi-
nation of antibiotics with other non-
oral formulations that include the
transdermal patch, injectables, or pro-
gestin implants. Studies of OCs included
a range of doses and progestins, but
none included the lowest dose pills (ie,
containing <30 mg EE or <150 mgmerican Journal of Obstetrics& Gynecology 95
Systematic Reviews ajog.orglevonorgestrel). We did not attempt
to normalize findings based on EE or
progestin dosing. Therefore, the find-
ings of this review may not extrapo-
late to the lowest dose pills that
contain 10e25 mg EE or <150 mg
levonorgestrel.
Theoretic mechanisms for contra-
ceptive failure with antibiotics include
alterations in drug absorption or meta-
bolism. Decreases in intestinal bacteria,
which transform orally ingested EE
before absorption and enterohepatic
circulation by the small intestine, could
reduce absorption of contraceptive ste-
roids.43 However, enterohepatic circula-
tion contributes relatively little to
circulating EE and progestin levels for
most women, so its reduction is unlikely
to have a significant effect on systemic
levels.43,44 Metabolismmay be altered by
induction or inhibition of hepatic en-
zymes. Rifampin is the only antibiotic
known to induce CYP enzymes, which
could increase the rate of EE and pro-
gestin metabolism and potentially
compromise contraceptive effect.3
Although some antibiotics are known
inhibitors of CYP enzymes (ciprofloxa-
cin, clarithromycin, erythromycin,
metronidazole, trimethoprim, and tele-
thromycin),3 this interaction would in-
crease steroid levels, which would not
compromise contraceptive mechanisms
but theoretically could increase side-
effects. Studies of UPA and E2V/dieno-
gest reported increases in steroid
hormones when co-administered with
erythromycin, but side-effects did not
increase for UPA and were not reported
for E2V/dienogest.33,37 Finally, antibi-
otics could reduce biologically active
progestin levels through increased
production of sex hormone binding
globulin, which is an hepatic protein that
binds progestins. Although rifampin
induces the production of sex hormone
binding globulin, other antibiotics do
not.2
Despite the reassuring evidence pre-
sented in this review, there are individual
variations in CYP metabolism that are
based on genetics and ethnicity, and
there may be a small subset of women
(likely <1%) who are more susceptible
to HC failure at baseline because of these96 American Journal of Obstetrics& Gynecologyfactors.44,45 Likewise, enterohepatic cir-
culation is altered in obesity, and it is
unknown whether obese women are
more susceptible to drug interactions as
a result. Contraceptive failure on a
particular method, particularly when
compliance has been good,may suggest a
higher risk of repeat failure on that
method, and such women should
consider switching to a more effective
method or adding backup
contraception.
Comparison with existing literature
Our findings are consistent with current
contraceptive guidance from the 2016
United States Medical Eligibility Criteria
for Contraceptive Use6 and the 2015
World Health Organization Medical
Eligibility Criteria for Contraceptive
Use,5 which recommend no restriction
for the use of any method of HC with
broad spectrum antibiotics. Likewise,
the most recent guidance for dental
practitioners46 and from the American
Academy of Dermatology Association47
no longer advise use of additional con-
traceptive protection during use of non-
rifamycin antibiotics.
Conclusions and implications
Existing evidence does not support drug
interactions between HC and non-
rifamycin antibiotics. Data are limited
by insufficient quantity and quality for
some antibiotic drug classes (particularly
metronidazole, sulfa drugs, and nitro-
furantoin) and non-OC formulations.
Most women can expect no reduction in
HC effect with concurrent use of non-
rifamycin antibiotics. To maximize the
effectiveness of user-dependent methods
like OCs, providers should encourage
correct and consistent use at all times,
including during illness. -
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Appendix A Search strategy
MEDLINE: (Contraceptive Agents, Fe-
male/ OR exp Contraceptives, Oral/ OR
exp Intrauterine Devices, Medicated/)
OR ((Levonorgestrel/ OR Ethinyl
Estradiol-Norgestrel Combination/ OR
exp Progesterone/ OR exp Progestins/)
and (contracept* OR birth con-
trol).ti,ab,kf,hw.) OR ((progest* OR Le-
vonorgestrel OR ethinylestradiol OR
estradiol OR Norgestrel OR etonogestrel
OR oral OR pill OR tablet OR hormon*
OR steroid OR inject* OR depo*
OR medroxyprogesterone OR dmpa OR
net-en OR norethisterone enanthate
OR patch* OR transdermal OR implant*
OR long acting OR intravaginal OR
intra-vaginal OR ring* OR post coital
OR postcoital) AND (contracept* OR
birth control)).ti,ab,kf,hw. OR (nor-
plant* OR (intrauterine ADJ2 device*)
OR (intra-uterine ADJ2 device*) OR
(intrauterine ADJ2 contracept*) OR
(intrauterine ADJ2 system*) OR (intra-
uterine ADJ2 contracept*) OR (intra-
uterine ADJ2 system*) OR LNG-IUS OR
IUD? OR IUS OR IUCD? OR ((intra-
vaginal OR intra-vaginal OR vaginal)
ADJ2 ring*)).ti,ab,kf,hw.
AND
Exp anti-infective agents/ or exp anti-
bacterial agents/ or exp antifungal agents/
or exp anti-infective agents, local/ or exp
antiparasitic agents/ or antiviral agents/
OR (Anti-infective OR anti-microbial OR
antimicrobial OR antiinfective OR anti-
biotic* ORmicrobicide*OR antiviral* OR
anti-viral* OR anti-fungal* OR anti-
fungal* OR fungicide* OR antimalarial*
OR anti-malarial* OR antiparasitic* OR
anti-parasitic* OR antibacterial* OR anti-
bacterial* OR bacteriocid* OR anti-
mycobacterial* OR anti-mycobacterial*
OR antiparasitic* OR anti-parasitic* OR
parasiticide*).ti,ab,kf,hw.
EMBASE: (Contraceptive Agent/
OR exp oral contraceptive agent/ OR
exp intrauterine contraceptive device/
OR injectable contraceptive agent/
or postcoitus contraceptive agent/)
OR ((Levonorgestrel/ OR Ethinyl
Estradiol-Norgestrel Combination/ OR
exp Progesterone/ OR exp Progestins/)
and (contracept* OR birth control).ti,ab.)
OR ((progest* OR Levonorgestrel OR
ethinylestradiol OR estradiol OR Norges-
trel OR etonogestrel OR oral OR pill OR
tablet OR hormon* OR steroid OR inject*
OR depo* OR medroxyprogesterone OR
dmpa OR net-en OR norethisterone
enanthate OR patch* OR transdermal OR
implant* OR long acting OR intravaginal
OR intra-vaginal OR ring* OR post coital
OR postcoital) AND (contracept* OR
birth control)).ti,ab. OR (norplant* OR
(intrauterine ADJ2 device*) OR (intra-
uterine ADJ2 device*) OR (intrauterine
ADJ2 contracept*) OR (intrauterine ADJ2
system*) OR (intra-uterine ADJ2 contra-
cept*) OR (intra-uterine ADJ2 system*)
OR LNG-IUS OR IUD? OR IUS OR
IUCD?OR((intravaginalOR intra-vaginal
OR vaginal) ADJ2 ring*)).ti,ab.
AND
antiinfective agent/ OR exp quinoline
derived antiinfective agent/ OR anti-
bacterial agents/ OR antifungal agents/
OR antiparasitic agent/ OR antibiotic
agent/ OR (Anti-infective OR
anti-microbial OR antimicrobial OR
antiinfective OR antibiotic* OR micro-
bicide* OR antiviral* OR anti-viral* OR
anti-fungal* OR antifungal* OR fungi-
cide* OR antimalarial* OR
anti-malarial* OR antiparasitic*
OR anti-parasitic* OR antibacterial* OR
anti-bacterial* OR bacteriocid* OR
antimycobacterial* OR anti-
mycobacterial* OR antiparasitic* OR
anti-parasitic* OR parasiticide*).ti,ab.
Cochrane: ([mh “Contraceptive
Agents, Female”] OR [mh “Contracep-
tives, Oral”] OR [mh “Intrauterine De-
vices, Medicated”]) OR (([mh
Levonorgestrel] OR [mh “Ethinyl
Estradiol-Norgestrel Combination”] OR
[mh Progesterone] OR [mh Progestins])
and (contracept* OR birth con-
trol):ti,ab) OR ((progest* OR Levonor-
gestrel OR ethinylestradiol OR estradiol
OR Norgestrel OR etonogestrel OR oral
OR pill OR tablet OR hormon* OR ste-
roid OR inject* OR depo* OR medrox-
yprogesterone OR dmpa OR net-en OR
norethisterone enanthate OR patch* OR
transdermal OR implant* OR long
acting OR intravaginal OR intra-vaginal
OR ring OR post coital OR postcoital)
AND (contracept* OR birth con-
trol)):ti,ab OR ((intrauterine NEAR/2
device*) OR (intra-uterine NEAR/2 de-
vice*) OR (intrauterine NEAR/2 con-
tracept*) OR (intrauterine NEAR/2
system*) OR (intra-uterine NEAR/2
contracept*) OR (intra-uterine NEAR/2
system*) OR LNG-IUS OR IUD? OR
IUS OR IUCD? OR ((extrauterine OR
extra uterine) NEAR/2 coil*)
OR ((intravaginal OR intra-vaginal OR
vaginal) NEAR/2 ring*)):ti,ab
AND
[mh “anti-infective agents”] OR [mh
“anti-bacterial agents”] OR [mh “anti-
fungal agents”] OR [mh “antiparasitic
agent”] OR [mh “anti-infective agents,
local”] OR [mh “antiviral agents”] OR
(Anti-infective OR anti-microbial OR
antimicrobial OR antiinfective OR anti-
biotic* OR microbicide* OR antiviral*
OR anti-viral* OR anti-fungal*
OR antifungal* OR fungicide* OR anti-
malarial* OR anti-malarial* OR anti-
parasitic* OR anti-parasitic* OR
antibacterial* OR anti-bacterial* OR
bacteriocid* OR antimycobacterial*
OR anti-mycobacterial* OR antipara-
sitic* OR anti-parasitic* OR
parasiticide*):ti,ab
Clinicaltrials.gov: “antimicrobial and
contraception” “antibiotic and
contraception”
Simmons. Antibiotics and hormonal
contraception. Am J Obstet Gynecol
2018.
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APPENDIX B
Evidence from observational studies
Study and
funding Study design Population Exposures Confounders Outcomes Results Strengths Weaknesses
Quality
rating
Helms et al
(1997);
funding
not stated
Retrospective
cohort
Antibiotic exposed:
578 women with
concurrent antibiotic/
OC prescriptions in 3
dermatology
practices over 5
years; 356 of these
women completed
surveys and included
in analysis.
Unexposed:162
women in same
practices who took
OCs without
antibiotics, plus 263
exposed women with
control periods of no
antibiotic use
From medical
records: OC use (any
active prescription);
any antibiotic use in
record during OC use
(confirmed
concurrent use by
survey)
Age, marital status,
particular antibiotic
and OC length of
combined exposure,
sexual activity during
combined exposure,
and use of barrier
contraception;
adjusted only for age
Pregnancy: Noted in
medical record or
reported by survey
and confirmed by
telephone call.
Powered to detect
difference of 2
pregnancies per 100
woman-years
Pregnancy
rates:Antibiotics and
OCs:1.6/100 woman-
years.
OCs alone: 0.96/100
woman years (p¼.4).
Five pregnancies on
concurrent antibiotics
(n¼3 minocycline
and 2¼
cephalosporin), some
of these had missed
OC doses and also
had pregnancies
while on OCs alone
Adjusted for age;
excluded women not
at risk of pregnancy
or using other
contraception;
performed subgroup
analyses for 2 control
groups with same
results
Control group older;
antibiotics grouped
together; did not
adjust for pill
compliance;
exposure/outcome
assessment limited
by survey/chart
review; possible
misclassification if
antibiotics used but
not prescribed by this
practice; 62%
response rate
II-2;
Fair
Jick et al
(2009);
funded
by Ortho
McNeil
Janssen
Nested case
control
Database of 300
general practitioners
in United Kingdom.
Cases: Unintended
pregnancy in
database with script
for HC within 4 mo
(n¼1129), verified a
sample of these by
medical record.
Control subjects: 4
Control subjects per
case matched by age,
practice, and year, on
HC with no pregnancy
(n¼4374)
HC: Script in
database for OC or
patch. Antibiotic: Any
script within 16
weeks of index
pregnancy
Collected data on
body mass index,
smoking, duration of
contraceptive use,
previous abortions
and deliveries,
sexually transmitted
infection history,
alcohol/drug use,
postpartum status,
and use of antibiotics
and anticonvulsants
for case control
Pregnancy: By codes
for unintended
pregnancy or
termination of
pregnancy. Reviewed
medical records to
validate diagnosis
and timing of
exposure/outcome
Antibiotic use not
associated with
unintended
pregnancy: OR, 1.0
(95% CI, 0.8e1.2).
Adjustment for
likelihood of exposure
(based on timing of
antibiotic use) did not
change the OR
Low risk of selection
bias; examined
multiple potential
confounders; large
sample size;
subgroup analyses by
likelihood and timing
of exposure all
consistent
Did not examine
antibiotics as a risk
factor for pills and
patch separately; did
not assess
compliance;
attempted to validate
exposure status by
provider
questionnaire but
only surveyed 8%; up
to 36% of pill user
cases not exposed,
and up to 59% of
patch users not
exposed;
misclassification
bias; outcome
assessment may
have missed
pregnancies not
coded as unplanned
II-2;
Poor
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APPENDIX B
Evidence from observational studies (continued)
Study and
funding Study design Population Exposures Confounders Outcomes Results Strengths Weaknesses
Quality
rating
Koopmans
et al (2012);
funding
not stated
Case cross-
over study
Mothers 15e49
years old, living
with their child,
identified through
a pharmacy
dispensing
database in the
Netherlands.
Cases: Pregnancies
in OC users (n¼397)
OC: OC script
picked up from an
outpatient pharmacy
in first 3 mo of
pregnancy (not first
time users).
Antibiotic: Any script
for antibiotic during
exposure window
Self-control Odds of exposure
to antibiotic during
exposure/control
window. EW: 15 days
before and after
probable conception
(DOB - 270 days). CW
1: month starting
2 mo before EW;
CW 2: month
exactly 1 year
before EW. Subgroup
analysis: broad
spectrum antibiotics
Breakthrough
pregnancies
accounted for
1.3% of total
pregnancies in
database. Case
crossover OR: 2.00
(95% CI, 0.89e4.79)
for control window 1
and OR, 1.42 (95% CI,
0.64e3.25) for
control window 2.
Sensitivity analysis:
Broad spectrum abs:
OR, 0.86 (95% CI,
0.24e2.98) for CW1
and OR, 0.71 (95% CI,
0.18e2.61) for CW2
No selection bias with
self-controls;
sensitivity analysis
with same conclusion
Database limited to
women living with
their child (estimated
35% pregnancies
excluded); exposure/
outcomes limited
entirely to database;
no external
validation; proportion
of breakthrough
pregnancies only
1.3%, which seems
low and suggests
misclassification
II-2;
Poor
Toh et al
(2011);
unfunded
Case cross-
over study
Unplanned
pregnancies in the
Sloane Epi Center
Birth Defects Study
and National Birth
Defects Prevention
Study, both
interview-based
databases. Cases:
1330 Reported
unplanned
pregnancies while
on OCs
OC: Use of OCs the
month before and
during conception (as
recorded in
database). Antibiotic:
Any antibiotic use in
database during
reference time
periods
Self-control; adjusted
for transient factors
like infection
Self-matched OR
comparing antibiotic
use for 4 wks before
conception (case
period) and 4e8 wks
before conception
(control period).
Additional sensitivity
analyses: (1)
alternate control
period, (2) stratified
by antibiotic class, (3)
databases separately
and combined (no
heterogeneity found
and therefore
combined)
Rate of antibiotic use
was 4% during case
period and 3.8%
during control period.
Self-matched OR,
1.08 (95% CI, 0.63
e1.84) for women
who took antibiotic in
only 1 of the 2 time
periods. Adjusting for
urinary tract infection
of upper respiratory
infection, OR, 1.1
(95% CI, 0.63e1.93)
No diff by smoking,
alcohol use body
mass index. Alternate
control period: OR,
1.45 (95% CI, 0.85
e2.5) for antibiotic
overall and OR, 1.55
(95% CI, 0.72e3.3)
for ampicillin/
amoxicillin
No selection bias with
self-control; large
sample size;
exposure assessment
obtained by
structured interview;
consistent findings in
sensitivity analyses
Did not control for
sexual activity,
backup
contraception;
unclear
generalizability;
databases use
primarily women with
birth defects who
may have recall bias
about medication use
II-2;
Fair
abs, antibiotics; CW, control window; DOB, date of birth; EW, exposure window; HC, hormonal contraception; OC, oral contraceptive pill; OR, odds ratio.
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APPENDIX C
Evidence for penicillins/cephalosporins
Study and funding
Study
design Population
Exposures
(HC, antibiotic) Outcomes Results Strengths Weaknesses
Quality
rating
Adlercreutz et al
(1984); Ford
foundation, Singrid
Juselius Foundation,
Yrjo Jahnsson
Foundation, Medical
Research Council of
the Academy of
Finland
PK; single
sequence
crossover/
parallel
groups
11 Healthy post-
menopausal women
(hospital employees);
ages and BMI not
reported
1: 10 mg NET for 10
d (n¼3), 5 mg
NET for 10 d
(n¼1), then
10 mg NET (n¼2) or 5
mg NET (n¼1) for 13 d
2: 50 mg EE, 250 mg
lynestrenol or 50 mg EE
with 2 mg NET daily
(n¼4). Oral ampicillin
500 mg 4 times daily,
days 5e8
1: Daily serum
levels (Cmin) and
day 4 and 8 PK.
2: Day 8 PK
1: No change to NET
levels with NET/
ampicillin co-
administration.
2: No change to EE with
ampicillin co-
administration (values
and statistics not
reported)
Perpetrator
drug at steady
state
Not randomized; no
clear study design;
small sample size;
adherence not
assessed; PK
parameters and timing
not uniform; no
information on potential
confounders;
postmenopausal
population with
uncertain
generalizability
Poor
Back et al (1982);
supported by MRC,
WHO, Mersey Health,
Wellcome trust,
Wyeth
PK and PD;
single
sequence
crossover
Group 1: 7 women
with UTI or URI taking
OCs for at least 3 mo,
ages 19e27 y, BMI
not reported. Group
2: 6 healthy women
taking OCs at least 3
mo, ages 21e24 y,
BMI not reported
G1: OCs with 30 mg EE
and 250 mg LNG (n¼5);
30 mg EE and 150 mg
LNG (n¼1); 50 mg EE
and 1 mg NET (n¼1).
G2: OCs with 30 mg EE
and 250 mg LNG (n¼5),
30 mg EE and 150 mg
LNG (n¼1). Ampicillin
500 mg 3 times daily for
8 days during either
cycle 1 or 2
EE and progestin PK on
days 5e8 cycle 1 and
cycle 2.
Group 2 only: ovulation
by serum P days 21 and
23, break-through
bleeding
G1: Ampicillin, no
ampicillin; mean EE,
46.4  15.2 pg/mL,
60.2  14.8 pg/mL
(NS); mean LNG, 2.0 
0.3 ng/mL, 2.05  0.4
ng/mL (NS). G2:
Ampicillin, no
ampicillin; mean EE,
28.2  2.8 pg/mL, 31.4
 5 pg/mL (NS); mean
LNG, 2  0.59 ng/mL,
2.13  0.63 ng/mL
(NS). No elevations in
serum P, no
breakthrough bleeding
Measured
ampicillin
level to assess
adherence
Not randomized; small
sample size; PK looking
only at steady state 12
and 24 hr after dose; no
information on potential
confounders; ampicillin
not detected in serum of
4 of 7 G1 patients,
which raises question of
validity of results
Poor
Friedman et al
(1980); funded by
Searle and Co
PD; single
sequence
crossover
11 Healthy women;
ages 21e39 y, BMI
not reported
OC with 50 mg EE and 1
mg ethynodiol acetate
for 3 cycles. Ampicillin
250 mg or placebo 4
times daily on days 1
e16 for 2 consecutive
cycles
Serum P on days 13 and
19; side-effects and
break-through bleeding
P levels under luteal
phase levels in all
cycles; 2 women had
breakthrough bleeding
in ampicillin cycle, 1 in
the placebo cycle
Both drugs at
steady state
Not randomized; small
sample size; adherence
not assessed; no
information on potential
confounders; P4 levels
measured on day 19,
which may have missed
peak
Poor
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APPENDIX C
Evidence for penicillins/cephalosporins (continued)
Study and funding
Study
design Population
Exposures
(HC, antibiotic) Outcomes Results Strengths Weaknesses
Quality
rating
Hempel et al (1978);
funding not stated
PD; single
sequence
crossover
20 Healthy
women
with regular
menstrual cycles;
age and BMI
not reported
OC with 50 mg EE
and 1 mg NET for at
least 6 mo. Ampicillin
500 mg 4 times daily
(duration not stated)
Frequency of bleeding
irregularities
0/20 with disordered
bleeding by historical
report; 2/20 with
breakthrough bleeding;
1/20 with no withdrawal
bleeding after addition
of ampicillin
Retrospective control
period; no justification
of sample size;
adherence not
assessed; no
information on potential
confounders; no
information on outcome
assessment
Poor
Joshi et al (1980);
supported by
Schering, World
Health Organization
PK and
PD;
single
sequence
crossover
6 Healthy women,
ages 20e36 y, BMI
not reported
OC with EE 30 mg
and NET 1 mg.
Ampicillin 500 mg
twice daily
for 5e7 days
starting day 6e7
of OC
EE and NET PK before
start of ampicillin and
again on last day of
treatment; ovulation
by serum P on days
19e23
EE: (before, after
ampicillin)
AUC0-6 397  46, 376
 71 (NS);
Cmax 90  11 pg/mL,
91  13 pg/mL (NS).
NET: (before/after
ampicillin)
AUC0-24125  20, 128
 19 (NS);
Cmax 11.1 2.1 ng/ml,
13.7  2.3 ng/ml (NS).
P levels anovulatory in
all cycles
PK parameters
and timing
appropriate,
both drugs
at steady state
Not randomized; small
sample size; adherence
data by recall only; no
information on potential
confounders
Fair
Philipson (1979);
funding not stated
PK; single
sequence
crossover
10 Healthy women
taking OCs; ages
20e32, weight
range 50e71kg
OCs with 50 mg EE
and 0.25 mg LNG
(n¼8), 50 mg EE and 0.5
mg LNG (n¼1), 50 mg
EE and 2.5 mg
lynestrenol (n¼1). One
dose 500 mg ampicillin
on day 21 and 28 of
cycle
Ampicillin PK Ampicillin mean
plasma level lower
at 1 hr after dose
when co-administered
with OC (numbers not
provided; P<.05), no
difference over
remaining 8 hr or with
Cmax, AUC0-8, or
clearance
PK parameters
appropriate; some
attempt to minimize
intersubject variability;
perpetrator drug at
steady state
Not randomized; small
sample size; timing of
ampicillin dose to OC
not addressed;
adherence not assessed
Fair
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APPENDIX C
Evidence for penicillins/cephalosporins (continued)
Study and funding
Study
design Population
Exposures
(HC, antibiotic) Outcomes Results Strengths Weaknesses
Quality
rating
Wise and Reeves
(1975); funding not
stated
PK; single
sequence
crossover
4 Healthy women taking
OCs; ages and BMI not
reported
Unspecified OC
formulations; 500 mg
cephaloridine IM on day
21 and again on day 28
Cephaloridine levels
over 8-hr period
Cephaloridine:
Cmax 18.9 mg/mL
with OCs and
23.5 mg/mL without
PK parameters and
timing appropriate;
perpetrator drug at
steady state
Not randomized; small
sample size; adherence
not assessed; no
information on potential
confounders; no
information on type of
OC; no statistics
performed
Poor
AUC, area under the curve; BMI, body mass index; Cmax, maximum serum concentration; Cmin, minimum serum concentration; EE, ethinyl-estradiol; HC, hormonal contraception; IM, intramuscular; LNG, levonorgestrel; NET, norethindrone; NS, not significant;
OC, oral contraceptive pill; P, progesterone; PD, pharmacodynamics; PK, pharmacokinetic; URI, upper respiratory infection; UTI, urinary tract infection.
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APPENDIX D
Evidence for tetracyclines
Study and funding
Study
design Population
Exposure
(HC, antibiotic) Outcomes Results Strengths Weaknesses
Quality
rating
Hempel et al (1978);
funding not stated
PD; single
sequence
crossover
15 Healthy women
with regular
menstrual cycles;
age and BMI not
reported
OC with 50 mg EE
and 1 mg NET for at
least 6 mo;
oxtetracycline
500 mg 4 times
daily, duration
not stated
Frequency of
bleeding
irregularities
0/15 with disordered
bleeding by historical
report; 0/15 with
breakthrough bleeding
with oxtetracycline
None Retrospective control
period; no justification
of sample size;
adherence not
assessed; no
information on potential
confounders; no
information on outcome
assessment
Poor
Murphy et al (1991);
National Institutes of
Health, National
Institutes of Child
Health and Human
Development
PK; single
sequence
crossover/
parallel
groups
7 Healthy women
(antibiotic group), 4
healthy controls; ages
18e35 y, BMI not
reported
OC with 35 mg EE
and 1 mg NET;
tetracycline 500 mg
every 4 hr for
5e10 d, starting
day 2 of OC
EE and NET PK day
0 and between days
5 and 10; tetracycline
AUC on day 1 and
between days
5 and 10
EE: No significant
changes in AUC or
Cmax with tetracycline.
NET: AUC and Cmax
rose over time (days 0
eday) when
administered with
tetracycline (P<.01).
Tetracycline: No
difference in
tetracycline Cmax and
AUC 0-4 with OCs vs 4
control subjects
(parallel analysis)
Adherence assessed
with pill counts, PK
parameters
appropriate,
perpetrator drug at
steady state
Not randomized; small
sample size; timing of
PK measurements
variable and within
subject comparisons
made at different times
of same cycle; no
information on potential
confounders
Poor
Neely et al (1991);
supported by West
Virginia Faculty
Senate and Johnson
and Johnson
PK and PD;
single
sequence
crossover
24 Women taking
OCs; ages 18e35 y,
BMI not reported
OC with 35 mg EE
and 1 mg NET for 2
cycles; doxycycline,
100 mg twice daily
days 14e21 in
cycle 2
EE and NET steady-
state levels on days
18-20; serum P
on days 18, 19,
20 of both cycles
EE: No significant
differences in
serum EE with/without
doxycycline (P¼.49);
NET: No significant
differences in serum
NET with/without
doxycycline (P¼.36).
None of the women had
P >0.8 ng/mL and no
difference in P between
cycles (P¼.32)
Sample size
reasonable, adherence
assessed with pill
counts, PK parameters
and timing appropriate,
minimized intersubject
variability, perpetrator
drug at steady state
Not randomized;
included ovulation as
an outcome, but timing
of serum P not likely to
be relevant, given
mid-cycle
administration of
doxycycline
Fair
AUC, area under the curve; BMI, body mass index; Cmax, maximum serum concentration; EE, ethinyl-estradiol; HC, hormonal contraception; NET, norethindrone; OC, oral contraceptive pill; P, progesterone; PD, pharmacodynamics; PK, pharmacokinetic.
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APPENDIX E
Evidence for fluoroquinolones
Study and funding Study design Population
Exposure
(HC and antibiotic) Outcomes Results Strengt
Quality
Amsden et al (2001);
support by Bassett
Healthcare
PK; parallel
groups
Controls: 10 White
women, mean age
33  7.4 y, using
non-HC. HC: 10 White
women, mean age 31
 7.4 y taking HC for at
least 3 mo. All normal
weight
OCs (n¼9); DMPA
(n¼1); single dose
200 mg trovafloxacin
Trovafloxacin PK
over 24 hr
Both groups did not
tolerate medicine in
fasted state with
neurologic or
gastrointestinal
symptoms in 80%
control, 90% HC. Cmax:
No HC 2.27 vs HC 1.92
mg/L (P¼.03).
Clearance: No HC 7.62
vs HC 9.96 L/h
(P<.004). AUC: No HC
26.7 vs HC 20.8 mg/L-h
(P<.004)
PK para
timing a
limited i
variabili
Back et al
(1991); supported
by Abbot
PK and PD;
single
sequence
crossover
12 Healthy women
on OCs at least
6 mo without
breakthrough
bleeding, ages
22e32 y, weight
range 44e79 kg
OC with 30 mg
EEþ150 mg LNG
(n¼11); 30 mg
EE and 250 mg LNG
(n¼1); temafloxacin
600 mg daily  7
d start of cycle 2
EE and progestin
levels on days 5e8
cycles 1 and 2;
ovulation by serum P
days 19e21
EE concentration 61.4
 21.1 pg/mL in
control cycle and 68.5
 26.6 pg/mL in
temafloxacin cycle
(NS). LNG
concentration 2.07
ng/mL in control cycle
and 1.89 in
temafloxacin cycle
(NS). Plasma P
concentration <1.0 ng/
mL in both control and
temafloxacin cycles
Adheren
by diary
temaflox
PK outc
timing a
limited i
variabili
at stead
Csemiczky et al
(1996); funding
not stated
PD;
randomized
crossover
(each with 2
cycles
placebo and
2 cycles
antibiotic)
20 Healthy women
on OCs at least 3 mo,
mean age 28.2 y,
mean BMI 22.1 kg/m2
OC with 30 mg
EEþ150 mg LNG;
ofloxacin 200 mg or
placebo twice daily
for first 7 d of each
cycle
P on days 19e21
(<3 nmol/L);
ultrasound 4 times
per cycle for follicle
>15 mm
No difference in
ovarian activity
between placebo and
ofloxacin cycles; 3
women had follicular
activity (follicle >15
mm) and high estradiol
levels in both placebo
and ofloxacin cycles; no
women ovulated based
on serum P
Random
blind, ad
diary ca
counts;
of obser
of P me
appropr
clear; m
follow u
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meters and
ppropriate;
ntersubject
ty
Not randomized;
parallel design; small
sample size; adherence
not assessed; unclear
whether HC at steady
state because time of
cycle not stated; pooled
2 hormonal methods
Poor
ce measured
card and
acin levels;
omes and
ppropriate;
ntersubject
ty; both drugs
y state
Not randomized;
sample size marginal;
data combined from
multiple pill
formulations
Fair
ized, double
herence by
rd and tablet
multiple cycles
vation; timing
asurement
iate; exposure
inimal loss to
p (n¼1)
Method of
randomization
unclear; no mention
of allocation
concealment;
sample size
calculations not
mentioned
Good
(continued)
System
atic
R
eview
s
APPENDIX E
Evidence for fluoroquinolones (continued)
Study and funding Study design Population
Exposure
(HC and antibiotic) Outcomes Results Strengths Weaknesses
Quality
rating
Droppert et al (1993),
funding not stated
PD;
randomized
crossover
24 Healthy women,
ages and weights
not provided
30 mg EE, 150
desogestrel;
ciprofloxacin 500 mg
twice daily or placebo
days 8e17 during
cycle 1 and cycle 3
Ovulation by
ultrasound
(follicle >18 mm)
and P4 at unspecified
times (<2 ng/mL)
No ovulations noted by
P; in 4 placebo and 4
Cipro cycles, follicles
>10 mm seen
eincomplete ovarian
suppression; 2 placebo
cycles had follicles
>18 mm
Randomized,
double blind
Unclear method of
randomization; no
mention of allocation
concealment; sample
size small for clinical
outcome; adherence
not assessed; timing of
ovulation assessment
not described; no
description of subjects
Poor
Maggiolo et al (1991);
supported by Bayer
PD;
randomized
crossover
10 Healthy volunteers
taking long-term
OCs, mean age
27.4 y; mean weight
61.4 kg, height
163.1 cm
OCs: EE 20e40
mgþgestodene 75 mg,
LNG 50e150 mg, or
desogestrel 150 mg (no.
not stated);
ciprofloxacin 500 mg or
placebo twice daily for
first 7 d of cycles
2 and 3
Bleeding pattern by
diary
No breakthrough
bleeding
Randomized;
adherence monitored
by pill tracking;
minimized intersubject
variability
Method of
randomization unclear;
no mention of
allocation concealment
Poor
Scholten et al (1998);
assistance from
Organon personnel
PK and PD;
randomized
crossover
24 Healthy women
using OCs for 3 mo;
ages 19e32 y; normal
weight
OC with 30 mg
EEþ150 mg
desogestrel;
ciprofloxacin
500 mg or placebo
twice daily days
1e10 of cycles
1 and 3
EE PK on days 11,16;
ovulation by serum P
(days 16, 20, 24, 28)
and ultrasound of
follicles on days 8, 10,
12, 14 (follicle >18
mm)
EE PK: Geometric
mean ratios for
AUC0-12, Cmax, and
t1/2 with and without
Cipro were within 80
e125% on days 11
and 16, considered
bioequivalent; no
P >2 ng/mL; 2 with
sustained follicular
growth (>10 mm) on
placebo without
ovulation
Randomized; sample
size adequate;
adherence measured
by Cipro levels; PK
parameters and timing
appropriate; minimized
intersubject variability;
drugs at steady state
Method of
randomization unclear;
no mention of
allocation
concealment; no
progestin PK; timing of
progesterone
measurements may
have missed ovulation
Good
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APPENDIX E
Evidence for fluoroquinolones (continued)
Study and funding Study design Population
Exposure
(HC and antibiotic) Outcomes Results Strengths Weaknesses
Quality
rating
Shain et al (2002);
supported by Bayer
PK; parallel
groups
Control: 15 Healthy
women, mean
age 37.6  7.2 y. HC:
15 Healthy
women, mean
age 31.1  8.6 y using
OC for at least 3 mo,
normal weight
Unspecified OCs;
single dose 400 mg
moxifloxacin
Moxifloxacin
PK over 48 hr
Moxifloxacin PK: NS
difference in Cmax,
Tmax, half-life
with and without OC.
AUC0-48: OC 34.5
mg*h/L vs non-OC
40.4 mg*h/L,
P¼.008. Clearance:
OC 191.3 vs non-OC
159.9 mL/min,
P¼.015; side-effects
common
Sample size
reasonable; PK
parameters
and timing
appropriate;
minimized
intersubject
variability
Not randomized; OC
adherence not
assessed; OC type
unspecified; timing of
moxifloxacin during
cycle not specified;
unclear whether OC at
steady state
Fair
AUC, area under the curve; BMI, body mass index; Cmax, maximum serum concentration; DMPA, depo-medroxyprogesterone acetate; EE, ethinyl-estradiol; HC, hormonal contraception; L-h, liters per hour; LNG, levonorgestrel; NS, not significant; OC, oral
contraceptive pill; P, progesterone; PD, pharmacodynamics; PK, pharmacokinetic; Tmax, time to maximum serum concentration.
Simmons. Antibiotics and hormonal contraception. Am J Obstet Gynecol 2018.
ajo
g.o
rg
System
atic
R
eview
s
JA
N
U
A
R
Y
2018
A
m
erican
Journalof
O
bstetrics
&
G
ynecology
97.e10
APPENDIX F
Evidence for macrolides
Study and funding
Study
design Population
Exposure (HC,
antibiotic) Outcomes Results Strengths Weaknesses
Quality
rating
Back et al (1991);
Abbott laboratories
PK and PD;
single
sequence
crossover
10 Healthy women
taking OCs, ages 19
e30 y, weight 46.3
e67.4 kg
OC with 30 mg EE
and 150 mg LNG
(n¼5) or 30 mg
EE and 150 mg
desogestrel
(n¼5), 250 mg
clarithromycin twice
daily days 1e7
during cycle 2
Days 5e8: 12 hr after
dosing. OC: Steady
state plasma EE, LNG,
3-keto desogestrel.
Days 19e21: Plasma P
EE: (clarithromycin/
without) 63.3/ 59.4 pg/
mL (NS). LNG: 2.01
/1.69 ng/mL (NS).
3Ketodsg: 3.35/ 1.43
ng/mL, P<.02
(increased). No rise in P
in either cycle
Adherence assessed
with tablet counts and
diaries and
clarithromycin levels on
days 5e7; PK
parameters and timing
appropriate; basic
subject characteristics
provided; perpetrator
drug at steady state
Not randomized;
small sample size
Fair
Blode et al (2012);
Bayer
PK; single
sequence
crossover
12 Healthy
postmenopausal
women (confirmed
by FSH, estradiol),
ages 45e75 y,
normal BMI
OC with estradiol
valerate 2 mg/DNG
3 mg days 1e14,
erythromycin 500 mg
3 times daily on
days 8e14
E2V and DNG PK,
antibiotic PK
E2: GMR of Cmax with/
without erythromycin:
151% (136e168%),
AUC0-24 133% (118
e150%). DNG: Cmax
133% (123e144%),
AUC0-24 162 (146
e180%). Steady state
exposure up to 33% for
E2 and 62% for DNG
Sample size
reasonable; PK
parameters and timing
appropriate; minimized
intersubject variability;
both drugs at steady
state
Not randomized;
adherence not
assessed; population
not reproductive
aged but explanation
provided
Fair
Fischer et al (2012);
Office of Women’s
Health, US Food and
Drug Administration;
National Institutes of
Health
PK; parallel
groups
25 Healthy women, 10
used OCs, ages >18 y,
weight within 25% of
ideal body weight
OC, unspecified
types, 500 mg
azithromycin day
1, 250 mg days
2e5
Azithromycin PK
on day 5 and
over the following 96
hours (16 samples)
Azithromycin: AUC
higher when
administered with OCs:
(mean difference, 11.4;
95% confidence
interval, 5.7e17.2 mg-
h/L). Clearance 38%
lower when
administered with OCs
Adherence assessed
by interview; diary
and plasma levels; PK
parameters
appropriate; basic
subject characteristics
provided; perpetrator
drug at steady state
Not randomized;
small sample size;
timing of azithromycin
in cycle not
standardized; OC type
and dose unspecified
Poor
Meyer et al (1990);
funding not stated
PD; single
sequence
crossover
22 Healthy women
using either IUD or
vasectomy,
ages >18 y, BMI
not reported
OC with EE 30/40/50
mgþLNG 50/75/125 mg
during cycles 2e4,
roxithromycin 150 mg
twice daily during
cycle 3
Ovulation by
ultrasound on day
13 to show
developing follicle
and day 21 serum P,
intermenstrual
bleeding by diary
All women ovulated
during baseline cycle.
OC alone: 0/22
ovulated
OCþroxithromycin:
0/22 ovulated. No
difference in
intermenstrual bleeding
during 3 OC cycles
Power calculation
discussed for 15%
risk of ovulation;
ultrasonographers
were blinded to
treatment; both drugs
at steady state
Not randomized;
bleeding outcomes
may be confounded
by use of IUD and
triphasic pill; no
information on
potential confounders
Fair
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APPENDIX F
Evidence for macrolides (continued)
Study and funding
Study
design Population
Exposure (HC,
antibiotic) Outcomes Results Strengths Weaknesses
Quality
rating
Wermeling et al
(1995); Lilly
PK and PD;
single
sequence
crossover
15 Healthy women
using OCs, ages
18e40 y, weight
within 15% of ideal
body weight
OC with 35 mg EE and
0.5/0.75/1 mg NET,
dirithromycin 500 mg
daily for 14 days (day
21 of cycle 2 through
day 8 of cycle 3)
EE PK on day 8 of both
cycles, ovulation by
serum P on day 21 of
cycle 3 and ultrasound,
breakthrough bleeding
EE: AUC decreased
7.6%with dirithromycin
(P¼.03); clearance
increased 10%
(P¼.03). No difference
to Cmax, Tmax, half-
life. No woman
ovulated in either
cycle. Intermenstrual
bleeding: 2 women with
OC alone but not with
dirithromycin 1; woman
with dirithromycin but
not OC alone
Sample size
reasonable;
adherence assessed
with pill diaries; PK
parameters and timing
appropriate; minimized
intersubject variation;
both drugs in steady
state
Not randomized Good
AUC, area under the curve; BMI, body mass index; Cmax, maximum serum concentration; DNG, dienogest; E2, estradiol; E2V, estradiol valerate; EE, ethinyl estradiol; FSH, follicle-stimulating hormone; GMR, geometric mean ratio; HC, hormonal contraception;
IUD, intrauterine device; LNG, levonorgestrel; NET, norethindrone; OC, oral contraceptive pill; P, progesterone; PD, pharmacodynamics; PK, pharmacokinetic; Tmax, time to maximum serum concentration.
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APPENDIX G
Evidence for other antibiotics and non-oral formulations of hormonal contraception
Study and
funding Study design Population
Exposure (HC and
antibiotic) Outcomes Results Strengths Weaknesses
Quality
rating
Hempel et al
(1978); funding
not stated
PD; single
sequence
crossover
39 Healthy women with
regular menstrual
cycles, age and BMI not
reported
EE: 50 mg/NET
unspecified.
Trimethoprim/
sulfamethoxazole 3
times daily (n¼21).
Nitrofurantoin 100 mg 4
times daily (n¼18),
unspecified duration
Frequency of bleeding
irregularities
Trimethoprim/
sulfamethoxazole 2/21
with disordered
bleeding. Nitrofurantoin
0/18 with disordered
bleeding
Retrospective control
period; no justification of
sample size; adherence
not assessed; no
information on
confounders; no
information on outcome
assessment
Poor
Joshi et al (1984);
supported by
Schering
PK; parallel
groups
10 Female leprosy
patients on dapsone, 6
healthy controls, ages
19e38 y, normal weight
One OC (1 mg
norethisterone and 30
mg EE) at 9 AM. Dapsone
100 mg 5 days per week
(long-term use)
NET and EE PK NET: Cmax Dapsone
14.6 vs 12.4 ng/mL
control; AUC0-24
Dapsone 88.8 vs 67.1
ng/mL/hr control; all NS
EE: AUC0-8 Dapsone
1041 vs 681 pg/ml/hr
(P<.05); Cmax 184
dapsone vs 128 pg/mL
control (NS)
PK parameters and
timing appropriate;
Dapsone at steady state
Not randomized; small
sample size; adherence
to Dapsone not
assessed; minimal
attempt to minimize
intersubject variation
Fair
Joshi et al (1980);
supported by
Schering, World
Health
Organization
PK and PD;
single
sequence
crossover
10 Healthy women
(PK and PD), 15
healthy women (PD
only), ages 20e36 y,
BMI not
stated
OC with EE 30 mgþNET
1 mg. Metronidazole
400 mg 3 times daily
for 6e8 days starting
cycle 2 day 7
EE and NET PK (before
and after completion of
antibiotic); ovulation by
serum P on days 19e23
EE AUC0-6 and NET
AUC0-24 did not change
significantly after
addition of
metronidazole. OCs did
not alter levels of
metronidazole. 3/25
Women on
metronidazole/OC had
ovulatory level P; 2/25
had high P during
control cycle
Borderline sample size;
PK parameters and
timing reasonable; both
drugs at steady state
Not randomized;
adherence to OCs
assessed, but by recall
only; minimal data on
intersubject variation;
multiple ovulations in
both groups concerning
for poor adherence or
assay problem
Fair
Mehrota et al
(1974); funding
not stated
Clinical;
parallel
groups
83 Female patients with
pulmonary TB but
otherwise healthy, with
<15 d of treatment,
ages 16e40 y, BMI not
stated
OCs: OC with 0.1 mg
mestranol and 1 mg
ethynodiol diacetate.
Antibiotics: 300 g
isoniazidþ150 mg
thiacetazone daily, plus
streptomycin 1g
injection twice weekly
for first 12 wk
TB status and safety
outcomes in each
group after 1 y
1 Patient died of
pulmonary TB in the no
OC group; 1 woman died
of other causes in OC
group. Sputum culture:
negative for 100% of OC
users at 1 year, and
negative for 94% of no
OC group
Randomized; groups
had similar disease
status at baseline by x-
ray and sputum cultures
Not blinded; no
information on
randomization scheme;
unclear power for
outcomes; adherence
not assessed; close to
20% LTFU in both
groups
Poor
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APPENDIX G
Evidence for other antibiotics and non-oral formulations of hormonal contraception (continued)
Study and
funding Study design Population
Exposure (HC and
antibiotic) Outcomes Results Strengths Weaknesses
Quality
rating
Dogterom et al
(2005); funded
by Organon
PK;
randomized
crossover
16 Healthy women per
drug, ages 18e40 y,
BMI 18e30 kg/m2
Combined vaginal ring
(15 mg EEþ120 mg of
ENG daily) for 21 days
with amoxicillin 875 mg
twice daily or
doxycycline 100 mg
daily on days 1e10 or
placebo during cycles
2 and 3
EE and ENG PK No differences in
etonogestrel or EE
steady-state levels or
AUC between subjects
using CVR with or
without either
antibiotic (GMRs
between 0.8
and 1.25)
Randomized with details
on randomization
scheme; adequate SS;
PK measures and timing
appropriate; adherence
monitored; minimized
intersubject variability;
both drugs at steady
state
None identified Good
Pohl et al
(2013); funded
by Preglem SA
PK; single
sequence
crossover
18 Healthy women,
mean age 26.4 y
(range, 19e41 y),
BMI 18.5e25 kg/m2
20 mg UPA on days 1
and 13. Erythromycin
500 mg twice daily on
days 9e17
UPA PK on days
1 and 13
Cmax increased by
24% (GMR, 1.24
(90% confidence
interval, 1.01e1.52);
AUC0-24 of UPA
increased 3.24 (2.75
e3.83; up 224%); no
change to Tmax or
half-life. For PGL4002
(UPA metabolite)
half-life doubled, Cmax
down by 48% (GMR
point estimate 0.523
[95% CI 0.44e0.62])
but AUC increased by
62% (GMR point
estimate 1.62 [95% CI
1.43-1.85]); no change
to Tmax
Sample size adequate;
standard PK parameters
and timing; compliance
monitored; limited
intersubject variability;
erythromycin at steady
state
Not randomized;
did not use
standard EC dose
Good
AUC, area under the curve; BMI, body mass index; Cmax, maximum serum concentration; CVR, contraceptive vaginal ring; EC, emergency contraception; EE, ethinyl estradiol; ENG, etonogestrel; GMR, geometric mean ratio; HC, hormonal contraception; LTFU, loss to
follow up; NET, norethindrone; NS, not significant; OC, oral contraceptive pill; P, progesterone; PD, pharmacodynamics; PGL, mono-demethylated metabolite of UPA; PK, pharmacokinetics; SS, sample size; TB, tuberculosis; Tmax, time to maximum serum
concentration; UPA, ulipristal acetate.
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